Management of Gastric Intestinal Metaplasia
Publication Date: December 9, 2019
AGA Recommendations for Management of Gastric Intestinal Metaplasia
In patients with GIM, the AGA recommends testing for H. pylori followed by eradication over no testing and eradication. ( Moderate , Strong )
611
In patients with GIM the AGA suggests against routine use of endoscopic surveillance.
Comments: Patients with GIM at higher risk for gastric cancer who put a high value on potential but uncertain reduction in gastric cancer mortality, and who put a low value on potential risks of surveillance endoscopies, may reasonably elect for surveillance.a ( Very Low , Conditional (weak) )
Comments: Patients with GIM at higher risk for gastric cancer who put a high value on potential but uncertain reduction in gastric cancer mortality, and who put a low value on potential risks of surveillance endoscopies, may reasonably elect for surveillance.a ( Very Low , Conditional (weak) )
Patients with GIM specifically at higher risk of gastric cancer include those with:
- Incomplete vs. complete GIM
- Extensive vs. limited GIM
- Family history of gastric cancer
- Racial/ethnic minorities
- Immigrants from high incidence regions
611
In patients with GIM, the AGA suggests against routine repeat short interval endoscopy with biopsies for the purpose of risk stratification.
Comments: Based on shared decision making, patients with GIM and high risk stigmata, concerns about completeness of baseline endoscopy, and/or who are at overall increased risk for gastric cancer (racial/ethnic minorities, immigrants from regions with high gastric cancer incidence, or individuals with family history of first-degree relative with gastric cancer) may reasonably elect for repeat endoscopy within 1 year for risk stratification. ( Very Low , Conditional (weak) )
Comments: Based on shared decision making, patients with GIM and high risk stigmata, concerns about completeness of baseline endoscopy, and/or who are at overall increased risk for gastric cancer (racial/ethnic minorities, immigrants from regions with high gastric cancer incidence, or individuals with family history of first-degree relative with gastric cancer) may reasonably elect for repeat endoscopy within 1 year for risk stratification. ( Very Low , Conditional (weak) )
a There are insufficient data to guide optimal surveillance interval. Based on indirect evidence regarding cumulative gastric cancer incidence among patients with GIM, repeat upper endoscopy with careful mucosal visualization and gastric biopsies of the antrum and body and any concerning lesions may be considered in 3-5 years among patients with incidentally detected GIM, if shared decision-making favors surveillance.
611
Recommendation Grading
Disclaimer
Overview
Title
Management of Gastric Intestinal Metaplasia
Authoring Organization
American Gastroenterological Association
Publication Month/Year
December 9, 2019
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
Inform management of patients with GIM incidentally detected on gastric biopsies in routine clinical practice.
Inclusion Criteria
Female, Male, Adult, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management
Keywords
Gastric Intestinal Metaplasia, GIM
Source Citation
Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, Falck-Ytter Y, Mustafa RA, AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia, Gastroenterology (2020), doi: https://doi.org/10.1053/j.gastro.2019.12.003.